

Faculty Disclosures

Name of Individual	Name of Ineligible Company(s)	Nature of Relationship(s)
Samina Afreen	Tandem Inc.	Research Funding
Monica Agarwal	Chair, Education Committee, The Obesity Society; Board of Directors for NBPNS	Consultant
Timothy Garvey	Fractyl Health; Alynham Pharmaceuticals; Novo Nordisk; Zealand; Merck; Allurion; Inogen; Neurocrine; Carmot/Roche; TERNS Pharmaceuticals; Keros Therapeutics; Regeneron	Advisory Board Consultant
	Boehringer-Ingelheim; Eli Lilly	Advisory Board Consultant; Member of a data monitoring committee
	Eli Lilly; Novo Nordisk; Pfizer; Epitomee; Neurovalens; Zealand; TERNS Pharmaceuticals; and Carmot/Roche	Research Funding; Site PI for the clinical trials
Marcio Griebeler	Novo Nordisk	Site PI for anti-obesity drug
Margaret Wierman	Crinetics	Research Funding to institution
Kathleen Wyne	Corcept; Abbvie; Ionis	PI, Research Funding to institution

All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.